Phase II, prospective, open-label study of a weekly schedule of irinotecan in patients with advanced colorectal cancer.

被引：0
|
作者：
Casinello, J
Dorta, J
Aguiar, J
Pérez-Carrión, J
Castellanos, J
Valladares, J
Sevilla, J
Belón, J
Fernández, J
Casal, J
机构：
[1] H Meixoeiro, Pontevedra, Spain
[2] H del Bierzo, Leon, Spain
[3] H Virgen de las Nieves, Granada, Spain
[4] H Virgen de la Victoria, Malaga, Spain
[5] H Juan Canalejo, La Coruna, Spain
[6] H Xeral Cies, Pontevedra, Spain
[7] H Princesa, Madrid, Spain
[8] H Gran Canarias, Madrid, Spain
[9] Na Sa Candelaria, Tenerife, Spain
[10] H Guadalajara, Tenerife, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
198P
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of Huachansu combined with adjuvant chemotherapy in resected colorectal cancer patients: a prospective, open-label, randomized phase II study
    Li, Shichao
    Shen, Dongxiao
    Zuo, Qingsong
    Wang, Shengzi
    Meng, Lingjia
    Yu, Jiaojiao
    Liu, Yang
    Li, Wusheng
    Chen, Chao
    Yin, Peihao
    Chen, Teng
    Wang, Jie
    MEDICAL ONCOLOGY, 2023, 40 (12)
  • [32] A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
    Kotani, Daisuke
    Yamaguchi, Kensei
    Kato, Ken
    Hara, Hiroki
    Miura, Akinori
    Satoh, Taroh
    Komine, Keigo
    Kunisaki, Chikara
    Yabusaki, Hiroshi
    Hagiwara, Akiko
    Suzuki, Noriko
    Toyoizumi, Kiichiro
    Curtin, Joshua C.
    Chowdhury, Sanjib
    Knoblauch, Roland Elmar
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 363 - 363
  • [33] An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer
    Raghav, K.
    Yoshino, T.
    Taniguchi, H.
    Tejpar, S.
    Vogel, A.
    Wainberg, Z.
    Yamaguchi, K.
    Fakih, M.
    Pedersen, K.
    Bando, K.
    Kawakami, H.
    Beck, J.
    Kanai, M.
    Liu, Y.
    Mekan, S.
    Pudussery, G.
    Qiu, Y.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S111 - S111
  • [34] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    J. Cassinello
    P. López-Alvarez
    A. Martínez-Guisado
    M. Valladares
    G. Huidobro
    R. López
    U. Bohn
    I. Sevilla
    P. Ballesteros
    M. Jorge
    R. Pérez-Carrión
    J. L. Fernández
    J. Dorta
    Medical Oncology, 2003, 20 : 37 - 43
  • [35] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    Cassinello, J
    López-Alvarez, P
    Martínez-Guisado, A
    Valladares, M
    Huidobro, G
    López, R
    Bohn, U
    Sevilla, I
    Ballesteros, P
    Jorge, M
    Pérez-Carrión, R
    Fernández, JL
    Dorta, J
    MEDICAL ONCOLOGY, 2003, 20 (01) : 37 - 43
  • [36] An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
    Bang, Yung-Jue
    Kaufman, Bella
    Geva, Ravit
    Stemmer, Salomon M.
    Hong, Sook-Hee
    Lee, Jong-Seok
    Domchek, Susan M.
    Lanasa, Mark C.
    Tang, Mei
    Gresty, Christopher
    Angell, Helen K.
    Opincar, Laura L. M.
    Herbolsheimer, Pia Maarit
    Evans, T. R. Jeffry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [37] Open-label, phase I/II dose-escalation study of ARANESP™ in patients with chronic anemia of cancer.
    Glaspy, J
    Meza, L
    Smith, R
    Fleishman, A
    Mendes, E
    Colowick, A
    BLOOD, 2000, 96 (11) : 154B - 155B
  • [38] An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.
    Moehler, M. H.
    Hartmann, J. T.
    Lordick, F.
    Al-Batran, S.
    Reimer, P.
    Trarbach, T.
    Ebert, M. P.
    Daum, S.
    Weihrauch, M.
    Galle, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
  • [40] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Shuntaro Obi
    Shigetoshi Fujiyama
    Shuichiro Shiina
    Hideyuki Tamai
    Hitoshi Mochizuki
    Yukihiro Koike
    Jun Imamura
    Takayoshi Yamaguchi
    Isamu Saida
    Osamu Yokosuka
    Masao Omata
    Hepatology International, 2014, 8 : 94 - 103
12345